top of page

Viral-vector therapies at scale: Today’s challenges and future opportunities


The majority of early viral-vector-based therapeutics were developed within the context of rare diseases, either through direct administration to certain tissues or (in the case of late-stage or on-market oncology cell therapies) through ex vivo cell modification. In these contexts, small quantities of viral vectors were required, particularly as most therapies were still in the clinical stage of development. Now, with the shift beyond ultra-rare indications, viral-vector manufacturing requires rapid expansion to be able to address these diseases in the commercial space.





21 views0 comments

Recent Posts

See All

Comments

Couldn’t Load Comments
It looks like there was a technical problem. Try reconnecting or refreshing the page.
bottom of page